Locations:
SearchAccess focus respects patient anxiety and fear
The time it takes for a person to receive their first therapy after diagnosis is a surrogate marker for the amount of empathy in a culture, says Chair of Physician Leadership and Development and former Chair of Taussig Cancer Institute Brian Bolwell, MD, FACP. It demonstrates respect for the level of anxiety and fear a cancer diagnosis can produce. It also cascades to other metrics required by the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Hear why Dr. Bolwell keeps pushing for progress in time to treat:
Dr. Bolwell is Chair of Physician Leadership and Development and former Chair of Taussig Cancer Institute. He can be reached at bolwelb@ccf.org or 216.444.6922. On Twitter: @BrianBolwellMD
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients